Systemic therapy of denosumab in altering surgical outcomes in patients with giant cell tumour of bone
To provide evidence on the benefits (i.e. effectiveness) and harms of DENO to inform provider/patient decision in patients with GCTB, BFHB, or ABC.
Skeletally mature adolescents (aged ≥ 12 years) and adults with GCTB, BFHB, or ABC undergoing DENO treatment. This includes patients with resectable disease, unresectable disease, recurrent disease, and primary disease.
Intended Guideline Users:
Medical oncologists, orthopedic oncologists, pathologists, and other clinicians involved in the care of patients with GCTB.
For patients with GCTB, BFHB, and ABC, what are the benefits and harms in terms of facilitation of surgery, disease recurrence, pain control, disease stability and adverse effects of denosumab use?